US equities |
NVDA $204.64 ▼-4.22% INTC $65.76 ▼-28.58% MU $884.74 ▼-5.30% AMZN $240.35 ▼-1.41% AAPL $344.63 ▼-1.23% SNDK $1,150.89 ▼-13.47% AMD $504.80 ▼-10.88% MSFT $521.91 ▼-1.55%
FinancialContent

Articles published by FibroBiologics, Inc.

< Previous 1 2 3 Next >
News headline image
FibroBiologics Receives Notice of Allowance for U.S. Patent Covering Topical Fibroblast Spheroid Therapy for Wound Healing
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics Advances Patient Dosing for Phase 1/2 Clinical Trial of CYWC628 for the Treatment of Diabetic Foot Ulcers
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics CEO Issues Letter to Shareholders
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics Compliant with All Nasdaq Listing Requirements
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics Presents Novel Thymus Organoid Platform to Combat Age-Related Immune Decline at Keystone Symposia on Aging and Immunity
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics Announces Closing of $3 Million Public Offering
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics Announces Pricing of $3 Million Public Offering
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical Trial
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Bid Price Requirement
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics to Present at the BIO Investment & Growth Summit
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics Granted Extension by Nasdaq to Regain Compliance
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics’ Chairman & CEO Pete O’Heeron Selected to Present at A4LI’s H-SPAN Summit at Georgetown University
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics to Present at the DealFlow Discovery Conference
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics CEO Issues Letter to Shareholders
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte (FSdC) Spheroid Therapy for Degenerative Disc Disease
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
News headline image
FibroBiologics Files IND Application with the U.S. FDA to Advance Clinical Development of CYPS317 in Patients with Psoriasis
From FibroBiologics, Inc.
Via GlobeNewswire
Tickers FBLG
< Previous 1 2 3 Next >